

INFORMATION DISCLOSURE STATEMENT (37 CFR 1.56, 1.97, and 1.98)		ATTORNEY DOCKET 25352-0029	APPLICATION NO. 09/977,059
		APPLICANT(S) Prasad V.V.S.V. Manchem et al.	
SHEET 1 OF 1		FILING DATE October 11, 2001	GROUP 1617

U.S. PATENT DOCUMENTS

* EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)

FOREIGN PATENT DOCUMENTS

* EX'R INITIAL	* REF. #	COUNTRY	PATENT NUMBER	DATE (MO/YR)	APPLICANT	TRANSLATION (YES/NO)

OTHER DOCUMENTS

* EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
	17	Yarasheski et al., "Insulin resistance in HIV protease inhibitor-associated diabetes", <i>J. Acquir. Immuno Defic. Syndr.</i> , 21, 209-216 (1999)
	18	Horn, "Postcard from Athens: Insulin resistance and more at the 3rd international workshop on lipodystrophy and adverse drug events in HIV", <i>The PRN Notebook™</i> , 6(4), 28-31 (2001), available on-line at www.pn.org

EXAMINER'S SIGNATURE		DATE CONSIDERED

* EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered.
Include copy of this form in next communication to applicant.

* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 USC 120. 37 CFR 1.98(d).